<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704675</url>
  </required_header>
  <id_info>
    <org_study_id>MP-VAC-105</org_study_id>
    <nct_id>NCT03704675</nct_id>
  </id_info>
  <brief_title>Effect of Food on the Pharmacokinetics of TEW-7197 in Healthy Subjects</brief_title>
  <official_title>Clinical Trial for the Safety, Tolerability, and Pharmacokinetics of TEW-7197 Under Fed or Fasting in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedPacto, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedPacto, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants in this study will receive 200 milligram (mg) TEW-7197 taken at 7days apart. One
      dose will be given under fasting . The Other dose will be given with a high fat meal. The
      study will evaluate the effect of a high fat meal on how much of the drug gets into the blood
      stream. Side effects will be documented. This study will last approximately 2weeks not
      including screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Through screening (D-30 ~ D-1) prior to the first dose of the investigational product, a
      total of 16 subjects (Group 1: 8 subjects, Group 2: 8 subjects) who were eligible for the
      inclusion criteria and exclusion criteria were enrolled. This clinical study has a
      randomized, open, single dose, 2-sequence, 2-period cross-over design and TEW-7197 50 mg x 4
      tablets were administered as a single dose in the same individual for 2 periods after fasting
      or a high fat diet, and each period was repeated with an interval of at least 1 week of
      wash-out. Pharmacokinetics and safety were evaluated in all subjects according to the planned
      schedule
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Actual">October 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 9, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics:Maximum Concentration (Cmax)</measure>
    <time_frame>Pre-dose through 24 hours post-dose in each period of the. study</time_frame>
    <description>Maximum Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics:Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Pre-dose through 24 hours post-dose in each period of the. study</time_frame>
    <description>Area Under the Concentration Curve (AUC) of TEW-7197</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group I (Fasted-&gt;Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II(Fed-&gt;Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEW-7197</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Group I (Fasted-&gt;Fed)</arm_group_label>
    <arm_group_label>Group II(Fed-&gt;Fasted)</arm_group_label>
    <other_name>Vactosertib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy sterile males

          2. BMI 18.0kg/m2 - 27.0 kg/m2

          3. No congenital or chronic disease and no pathological symptoms or pathological findings

          4. Investigator confirm that the subject is eligible through a medical examination
             (medical history taking ,vital signs, ECG, cardiac ultrasonography, blood science)

        Exclusion Criteria:

          1. Has pathological symptoms or pathological findings

          2. Has a history of disease that may affect the absorption, distribution, metabolism and
             excretion of a drug

          3. SBP&gt;140 or &lt;90 mmhg , DBP&gt;90 or &lt;60mmHg ,Pulse&gt;100

          4. No abnormal Clinical Lab findings
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunjin Hwang, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedPacto, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT03704675/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

